Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer

Rhea-AI Summary

Monopar (Nasdaq: MNPR) appointed Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In this newly created role she will lead commercial strategy and infrastructure as Monopar prepares a planned NDA submission for ALXN1840 in the first half of 2026.

Ms. Rodriguez brings over 30 years of biopharma commercial experience, including leadership roles at Avadel, Ardelyx, Tolmar, and Abbott, and experience launching rare-disease therapies and building commercial organizations.

Positive

• NDA submission for ALXN1840 planned in the first half of 2026
• Experienced hire: Susan Rodriguez with 30+ years in biopharma commercialization
• Track record of rare-disease launches and commercial infrastructure build-outs

Negative

• Role is newly created, indicating commercial infrastructure is still under development
• NDA submission timing (H1 2026) creates near-term regulatory dependence for value realization

Key Figures

Planned NDA timing: First half of 2026 Industry experience: More than 30 years Acquisition value: Over $2 billion +1 more

4 metrics

Planned NDA timing First half of 2026 Targeted NDA submission to FDA for ALXN1840 in Wilson disease

Industry experience More than 30 years Susan Rodriguez’s biopharmaceutical leadership background

Acquisition value Over $2 billion Value of Avadel acquisition by Alkermes where Rodriguez was COO

Therapeutic launches Two key therapeutics Number of therapeutics launched while at Ardelyx

Market Reality Check

Price: $54.80 Vol: Volume 113,151 vs 246,633...

low vol

$54.80 Last Close

Volume Volume 113,151 vs 246,633 20-day average (0.46x typical activity). low

Technical Price 54.805 is trading below 200-day MA at 58.35 and 47.8% under the 52-week high of 105.

Peers on Argus

Peers show mixed moves: ANNX +5.46%, LXEO +5.12%, ALEC -3.19%, LCTX -1.03%, FHTX...

1 Up 1 Down

Peers show mixed moves: ANNX +5.46%, LXEO +5.12%, ALEC -3.19%, LCTX -1.03%, FHTX 0%, indicating stock-specific factors for MNPR rather than a unified biotech move.

Historical Context

5 past events · Latest: Nov 13 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 13	Earnings and pipeline	Positive	+5.4%	Q3 2025 results, strong cash, NDA plan for ALXN1840, new IND clearance.
Nov 09	Clinical data update	Positive	+2.6%	Phase 2 ALXN1840 data showing rapid, sustained copper balance improvement.
Oct 15	Conference abstract	Neutral	-5.1%	Abstract acceptance for ALXN1840-WD-204 oral presentation at AASLD 2025.
Sep 23	Equity offering	Positive	+7.9%	$135M underwritten offering of stock and pre-funded warrants for corporate uses.
Sep 23	Peer-reviewed data	Positive	+7.9%	Journal letter showing significant ALXN1840 copper balance improvements with strong p-values.

Pattern Detected

Recent MNPR news, especially positive clinical, financing, and data updates, often aligned with same-day gains, with only one noted divergence on a neutral abstract announcement.

Recent Company History

Over the last six months, Monopar has advanced ALXN1840 with multiple data disclosures and financing steps. On Sep 23, 2025, a $135M equity and pre-funded warrant offering coincided with a 7.94% gain. A Journal of Hepatology letter on ALXN1840’s copper balance improvement the same day also matched a 7.94% move. Subsequent AASLD presentation data on Nov 9, 2025 and Q3 results plus NDA plans on Nov 13, 2025 were followed by gains of 2.63% and 5.36%, respectively, while an abstract-acceptance headline on Oct 15, 2025 saw a -5.11% reaction.

Regulatory & Risk Context

Active S-3 Shelf · $300,000,000

Shelf Active

Active S-3 Shelf Registration 2025-08-29

$300,000,000 registered capacity

An effective Form S-3 shelf filed on Aug 29, 2025 permits Monopar to offer up to $300,000,000 of securities (common stock, warrants, subscription rights, and units) over time, with one recorded usage via a 424B5 on Sep 24, 2025. Proceeds are designated for general corporate purposes per the base prospectus.

Market Pulse Summary

This announcement adds commercial depth as Monopar approaches a planned 2026 NDA filing for ALXN1840...

Analysis

This announcement adds commercial depth as Monopar approaches a planned 2026 NDA filing for ALXN1840 in Wilson disease, appointing a leader with more than 30 years of biopharma experience and involvement in a >$2 billion acquisition. It follows prior ALXN1840 data readouts, capital raises, and institutional ownership disclosures. Investors may watch for NDA submission progress, commercialization build-out, and any further use of the $300,000,000 shelf registration as key future indicators.

Key Terms

new drug application, nda, u.s. food and drug administration, fda, +3 more

7 terms

new drug application regulatory

"planned submission of a New Drug Application (“NDA”) to the U.S. Food and Drug"

A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.

nda regulatory

"planned submission of a New Drug Application (“NDA”) to the U.S. Food and Drug"

An NDA, or nondisclosure agreement, is a legal contract that keeps certain information private between parties. It’s like a promise not to share sensitive details, helping protect business ideas, strategies, or data from being leaked or used without permission. For investors, NDAs help ensure that confidential information remains secure, enabling trust and open communication during business discussions.

u.s. food and drug administration regulatory

"New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in"

The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.

fda regulatory

"Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in the first"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

wilson disease medical

"late-stage investigational therapy for Wilson disease. “Susan is a highly"

A genetic disorder that prevents the body from removing excess copper, causing copper to build up mainly in the liver and brain and leading to liver disease, movement problems, and cognitive or psychiatric symptoms. Investors pay attention because tests, drugs, gene therapies or diagnostic tools for this condition can drive regulatory approvals, clinical trial risk, and niche market opportunities; think of it as a small but high-need market where a successful treatment can meaningfully change company value.

oncology medical

"Chief Executive Officer of Tolmar Pharmaceuticals, a specialty oncology company,"

Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.

biopharmaceutical medical

"clinical‐stage biopharmaceutical company developing innovative treatments for patients"

A biopharmaceutical is a medicine made from living organisms or their components—such as proteins, cells or genetic material—rather than chemically synthesized compounds. For investors, these products can command high prices and long patent protection but also carry bigger development, manufacturing and regulatory risks; think of them like handcrafted, high-tech products that can generate strong returns if they work, but are costly and complex to produce.

AI-generated analysis. Not financial advice.

WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In this newly created executive role, Ms. Rodriguez will lead the Company’s commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson disease.

“Susan is a highly accomplished commercial and strategic leader with a distinguished track record of successfully launching innovative rare disease therapies and guiding organizations through high-growth phases,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer. “Her experience building strong-performing commercial teams will be invaluable as Monopar advances ALXN1840 toward approval. We are very excited to welcome her to the team.”

“I am delighted to join Monopar at such a pivotal moment in its evolution,” said Ms. Rodriguez. “ALXN1840 represents the first major advancement in the treatment of Wilson disease in decades, and I look forward to building the commercial capabilities necessary to ensure broad patient access and to maximize the therapy’s impact.”

Ms. Rodriguez brings more than 30 years of biopharmaceutical leadership experience. She most recently served as Chief Operating Officer of Avadel Pharmaceuticals, where she led the company’s commercial strategy and execution, contributing to the recently completed acquisition of Avadel by Alkermes for over $2 billion. Prior to Avadel, Ms. Rodriguez was Chief Commercial Officer of Ardelyx, where she established the company’s first commercial organization and successfully transitioned Ardelyx from a development-stage company to a commercial biopharmaceutical enterprise. She led the launches of two key therapeutics, building market access, sales, marketing, and patient services capabilities and delivering strong early adoption in highly competitive areas. Before that, she served as Chief Executive Officer of Tolmar Pharmaceuticals, a specialty oncology company, where she established a new U.S. commercial entity, secured a market-leading position for its primary oncology therapy, advanced its pipeline, and successfully launched a new rare disease therapy. Earlier, she held various commercial leadership positions across multiple divisions at Abbott as well as the Abbott–Takeda joint venture, TAP Pharmaceuticals. She holds an M.S. and a B.S. in psychology, with a minor in chemistry, from the University of Pennsylvania.

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company with late-stage ALXN1840 for Wilson disease, and radiopharmaceutical programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of advanced cancers. For more information, visit: www.monopartx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include statements concerning: that Ms. Rodriguez will lead the Company’s commercial strategy and infrastructure build-out; that Monopar prepares for the planned submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in the first half of 2026 for ALXN1840; that Ms. Rodriguez’s experience building high-performing commercial teams will be invaluable as Monopar advances ALXN1840 toward approval; and that Ms. Rodriguez looks forward to building the commercial capabilities necessary to ensure broad patient access and to maximize the therapy’s impact. The forward-looking statements involve risks and uncertainties including, but not limited to, the following: uncertainties related to the regulatory process that Monopar intends to initiate related to ALXN1840 and the outcome thereof; the rate of market acceptance and competitiveness in terms of pricing, efficacy and safety of any products for which Monopar receives marketing approval, and Monopar’s ability to competitively market any such products as compared to larger pharmaceutical firms; Monopar’s ability to raise sufficient funds in order for the Company to support continued preclinical, clinical, regulatory, precommercial and commercial development of its programs and to make contractual milestone payments, as well as its ability to further raise additional funds in the future to support any existing or future product candidate programs through completion of clinical trials, approval processes and, if applicable, commercialization; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Contact:

Monopar Therapeutics Inc.
Investor Relations
Quan Vu
Chief Financial Officer
vu@monopartx.com

Follow Monopar on social media for updates:    
X: @MonoparTx  LinkedIn: Monopar Therapeutics  

FAQ

What does Susan Rodriguez's appointment mean for Monopar (MNPR) commercial plans?

It signals an accelerated build-out of Monopar's commercial organization ahead of regulatory filing. According to Monopar, Ms. Rodriguez will lead commercial strategy and infrastructure as the company prepares an NDA submission for ALXN1840 in H1 2026.

When will Monopar (MNPR) submit the NDA for ALXN1840?

Monopar plans to submit an NDA for ALXN1840 in the first half of 2026. According to Monopar, the company is preparing the filing as it advances the late-stage investigational therapy for Wilson disease toward regulatory review.

What commercial experience does Susan Rodriguez bring to Monopar (MNPR)?

Ms. Rodriguez has over 30 years of biopharma commercial leadership and launch experience. According to Monopar, her background includes roles at Avadel, Ardelyx, Tolmar, and Abbott, and involvement in launches and a >$2 billion acquisition at Avadel.

How could the appointment of a Chief Commercial and Strategy Officer affect MNPR shareholders?

The hire may improve commercialization readiness ahead of regulatory milestones, potentially reducing execution risk. According to Monopar, the role focuses on building market access, sales, and patient services in advance of the planned H1 2026 NDA submission.